Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsBiotechnology Equipment

PUBLISHER: 360iResearch | PRODUCT CODE: 1497603

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1497603

Acute Care Syndromic Testing Market by Disease Type (Gastrointestinal Diseases, Genitourinary Diseases, Respiratory Diseases), Target (Bacteria, Fungi, Parasites), Sample Type, End User - Global Forecast 2024-2030

PUBLISHED:
PAGES: 192 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

Description

Table of Contents

List of Tables

[192 Pages Report] The Acute Care Syndromic Testing Market size was estimated at USD 3.40 billion in 2023 and expected to reach USD 3.74 billion in 2024, at a CAGR 9.99% to reach USD 6.63 billion by 2030.

Acute care syndromic testing refers to the rapid diagnostic process used in healthcare settings to identify the cause of a symptomatic patient's clinical symptoms by testing for multiple possible causes simultaneously. It facilitates qualitative detection and identification of viral, bacterial, fungal, and parasitic pathogens using real-time polymerase chain reaction (PCR). This approach is particularly significant in acute care settings where time-sensitive decisions are crucial, such as emergency departments or intensive care units. It employs panels of tests that cover a range of pathogens or conditions associated with a particular clinical syndrome, such as respiratory illness or gastrointestinal infection. The rise in infectious disease prevalence, including multi-drug-resistant pathogens, drives the need for rapid syndromic testing. Furthermore, government initiatives to improve medical infrastructure and stimulate the adoption of advanced diagnostics systems contribute to market growth. However, incidences of false positives and negatives and a lack of adequate reimbursements for certain syndromic tests can impede the adoption of acute care syndromic testing. Additionally, technical challenges and the ability to detect a limited number of microbial pathogens pose hurdles to the growth of the industry. However, key players are exploring the development of broader-ranging panels that can detect multiple pathogens in a single test. Research initiatives and advancements in clinical and medical microbiology can improve the performance and accuracy of acute care syndromic testing tools. Furthermore, the integration of advanced digital technologies such as AI/ML, data analysis technologies, and computational biology strategies can create new avenues of growth for the industry.

KEY MARKET STATISTICS
Base Year [2023] USD 3.40 billion
Estimated Year [2024] USD 3.74 billion
Forecast Year [2030] USD 6.63 billion
CAGR (%) 9.99%

Regional Insights

The Americas region, particularly the US and Canada, boasts a robust healthcare infrastructure and digitalized healthcare framework, significantly driving the adoption of acute care syndromic testing in hospitals and clinics. Additionally, the Centers for Disease Control and Prevention (CDC) and other federal bodies actively encourage the development of rapid syndromic testing methods. Health insurers and hospitals are significant customers, and their purchasing behavior reflects a preference for integrated solutions that can provide quick results and aid in antimicrobial stewardship. The EU puts emphasis on compliance with stringent regulations pertaining to the healthcare sector. Additionally, strong collaborations between academic institutions, key players, and research institutes have led to innovations and improvements in the field of diagnostics and syndromic testing. Increasing antimicrobial resistance has also propelled the need for advanced diagnostics tools. In the APAC region, growing focus on healthcare reform and government initiatives and funds to expand access to advanced medical services and facilities are key factors leading to the adoption of acute care syndromic testing. Players in South Korea, India, and China are collaborating with diagnostic testing laboratories to expand the spread of acute care syndromic testing.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Acute Care Syndromic Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising incidences of infectious disease outbreaks
      • Utilization of syndromic tests for detecting antimicrobial resistance
      • Government initiatives to expand treatment and diagnosis of sexually transmitted diseases
    • Market Restraints
      • Incidences of false positives and false negatives and chances of contamination
    • Market Opportunities
      • Efforts to include syndromic testing under stewardship programs
      • Advancements in clinical microbiology leading to improved testing strategies
    • Market Challenges
      • Technical limitations of acute care syndromic testing methods
  • Market Segmentation Analysis
    • Disease Type: Growing pollution levels and changing climate patterns leading to a surge in the prevalence of respiratory diseases
    • Target: Need for timely and rapid diagnosis of bacterial infections in acute care settings
    • Sample Type: Utilization of blood samples to facilitate detection of infections and sepsis
    • End User: Expanding private investments and government initiatives to upgrade hospital infrastructure
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Acute Care Syndromic Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Acute Care Syndromic Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Clears COVID-19 Home Antigen Test

The U.S. Food and Drug Administration (FDA) officially cleared ACON Laboratories' Flowflex COVID-19 Antigen Home Test for over-the-counter sales. This antigen test, which initially received Emergency Use Authorization in 2021, stands out as the second home diagnostic for COVID-19 to transition through a standard premarket evaluation by the FDA, marking a significant milestone. This development underscores the expansion of accessible testing options for the detection of COVID-19 for the public, including minors. [Published On: 2023-11-09]

Biden Government to Deliver Free COVID Tests To U.S. Households And Invest USD 600 Million In Domestic Manufacturers

The United States Department of Health and Human Services (HHS) confirmed its intent to combat the ongoing challenge posed by COVID-19 by providing American households with no-cost testing kits. The HHS has also unveiled an ambitious strategy, allocating USD 600 million to bolster the production capabilities of twelve domestic testing manufacturers, ensuring a robust response to the pandemic through the end of 2023. This strategic move underscores the continuing effort to keep citizens safe and well-informed amidst the evolving health crisis. [Published On: 2023-09-23]

NIH Launches Home Test to Treat a Pilot COVID-19 Telehealth Program

The U.S. National Institutes of Health, in partnership with the Administration for Strategic Preparedness and Response, has rolled out an innovative Home Test to Treat program, announced previously by the White House. This virtual community health initiative seeks to offer complimentary COVID-19 health amenities to designated communities, including at-home rapid tests, telehealth consultations, and treatment options. Through this program, individuals who test positive for COVID-19 using at-home tests are eligible to receive antiviral medications, enhancing their chances of averting serious illness, hospitalization, or death. [Published On: 2023-01-05]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Acute Care Syndromic Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Acute Care Syndromic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Applied BioCode, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, BIOHM Health LLC, bioMerieux SA, Curetis GmbH b y OpGen, Inc, CVS Health, Danaher Corporation, DiaSorin S.p.A, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Genetic Signatures Ltd., Hologic Inc., Luminex Corporation, Microbiologics, Inc., Pfizer, Inc., QIAGEN N.V., QuantuMDx Group Ltd., Seegene Inc., Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Werfen.

Market Segmentation & Coverage

This research report categorizes the Acute Care Syndromic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Gastrointestinal Diseases
    • Genitourinary Diseases
    • Respiratory Diseases
    • Tropical Diseases
  • Target
    • Bacteria
    • Fungi
    • Parasites
    • Viruses
  • Sample Type
    • Biofluids
    • Blood
    • Stool
    • Swabs
    • Urine
  • End User
    • Clinical & Diagnostic Laboratories
    • Hospitals
    • Research & Academic Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom
Show more
Product Code: MRR-5A3042B3D68E

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of infectious disease outbreaks
      • 5.1.1.2. Utilization of syndromic tests for detecting antimicrobial resistance
      • 5.1.1.3. Government initiatives to expand treatment and diagnosis of sexually transmitted diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of false positives and false negatives and chances of contamination
    • 5.1.3. Opportunities
      • 5.1.3.1. Efforts to include syndromic testing under stewardship programs
      • 5.1.3.2. Advancements in clinical microbiology leading to improved testing strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations of acute care syndromic testing methods
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Growing pollution levels and changing climate patterns leading to a surge in the prevalence of respiratory diseases
    • 5.2.2. Target: Need for timely and rapid diagnosis of bacterial infections in acute care settings
    • 5.2.3. Sample Type: Utilization of blood samples to facilitate detection of infections and sepsis
    • 5.2.4. End User: Expanding private investments and government initiatives to upgrade hospital infrastructure
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Acute Care Syndromic Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Gastrointestinal Diseases
  • 6.3. Genitourinary Diseases
  • 6.4. Respiratory Diseases
  • 6.5. Tropical Diseases

7. Acute Care Syndromic Testing Market, by Target

  • 7.1. Introduction
  • 7.2. Bacteria
  • 7.3. Fungi
  • 7.4. Parasites
  • 7.5. Viruses

8. Acute Care Syndromic Testing Market, by Sample Type

  • 8.1. Introduction
  • 8.2. Biofluids
  • 8.3. Blood
  • 8.4. Stool
  • 8.5. Swabs
  • 8.6. Urine

9. Acute Care Syndromic Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Clinical & Diagnostic Laboratories
  • 9.3. Hospitals
  • 9.4. Research & Academic Institutions

10. Americas Acute Care Syndromic Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acute Care Syndromic Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acute Care Syndromic Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Clears COVID-19 Home Antigen Test
    • 13.3.2. Biden Government to Deliver Free COVID Tests To U.S. Households And Invest USD 600 Million In Domestic Manufacturers
    • 13.3.3. NIH Launches Home Test to Treat a Pilot COVID-19 Telehealth Program
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio
Show more
Product Code: MRR-5A3042B3D68E

LIST OF FIGURES

  • FIGURE 1. ACUTE CARE SYNDROMIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ACUTE CARE SYNDROMIC TESTING MARKET DYNAMICS
  • FIGURE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE CARE SYNDROMIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GENITOURINARY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GENITOURINARY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY FUNGI, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRUSES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRUSES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BIOFLUIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BIOFLUIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BLOOD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STOOL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STOOL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SWABS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SWABS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY URINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 116. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 121. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 124. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 129. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 132. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 137. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 140. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 145. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 148. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 153. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 156. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 164. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 169. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 172. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 180. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 185. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 188. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 193. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 196. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 201. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 204. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 219. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 222. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 227. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 230. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 235. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 238. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 243. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 246. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 251. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 254. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 259. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 262. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 267. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 270. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 278. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 283. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 286. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 291. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 294. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 299. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 302. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 307. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 308. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 309. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 310. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 315. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 318. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. SAUDI ARABIA ACU
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!